{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:15:05Z","timestamp":1794550505658,"version":"4.9.1"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Biofilms Microbiomes"],"DOI":"10.1038\/s41522-025-00891-8","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T01:52:53Z","timestamp":1766368373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Microbiome dysbiosis and chemotherapy resistance in acute myeloid leukemia (AML)"],"prefix":"10.1038","volume":"12","author":[{"given":"Maojin","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6722-5015","authenticated-orcid":false,"given":"Seyed Shahabedin","family":"Alemohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8810-4559","authenticated-orcid":false,"given":"Milad Fakhraei","family":"Manesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5898-591X","authenticated-orcid":false,"given":"Farzaneh","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4808-3984","authenticated-orcid":false,"given":"Amirhossein","family":"Zeynalabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian, H. et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 11, 41 (2021).","journal-title":"Blood Cancer J."},{"key":"891_CR2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony, S., Stahl, M. & Stone, R. M. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. Am. J. Hematol. 100, 860\u2013891 (2025).","journal-title":"Am. J. Hematol."},{"key":"891_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short, N. J., Rytting, M. E. & Cortes, J. E. Acute myeloid leukaemia. Lancet 392, 593\u2013606 (2018).","journal-title":"Lancet"},{"key":"891_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-025-01764-2","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan, H. et al. Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. Clin. Exp. Med. 25, 215 (2025).","journal-title":"Clin. Exp. Med"},{"key":"891_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","volume":"8","author":"L Tang","year":"2023","unstructured":"Tang, L. et al. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct. Target Ther. 8, 306 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"891_CR6","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.3390\/cancers16244136","volume":"16","author":"C Wemyss","year":"2024","unstructured":"Wemyss, C., Jones, E., Stentz, R. & Carding, SR. Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia: Classification and Metabolic Characteristics for Informing and Advancing Treatment. Cancers (Basel) 16, 4136, https:\/\/doi.org\/10.3390\/cancers16244136 (2024).","journal-title":"Cancers (Basel)"},{"key":"891_CR7","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.3390\/ijms26094005","volume":"26","author":"S Cao","year":"2025","unstructured":"Cao, S., Wang, Q. & Zhu, G. From Chemotherapy to Targeted Therapy: Unraveling Resistance in Acute Myeloid Leukemia Through Genetic and Non-Genetic Insights. Int. J. Mol. Sci. 26, 4005 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"891_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53629-z","volume":"15","author":"AE Culver-Cochran","year":"2024","unstructured":"Culver-Cochran, A. E. et al. Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis. Nat. Commun. 15, 9189 (2024).","journal-title":"Nat. Commun."},{"key":"891_CR9","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3390\/jcm14082759","volume":"14","author":"M Farina","year":"2025","unstructured":"Farina, M. et al. Intensive Chemotherapy Versus Venetoclax-Based Regimens in Elderly Patients with Acute Myeloid Leukemia: Is the Chemotherapy Era Ending?. J. Clin. Med. 14, 2759 (2025).","journal-title":"J. Clin. Med."},{"key":"891_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu, H. Emerging agents and regimens for AML. J. Hematol. Oncol. 14, 49 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"891_CR11","doi-asserted-by":"publisher","unstructured":"Palmieri, R. et al. Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy. Blood Rev. 101288 (2025). https:\/\/doi.org\/10.1016\/j.blre.2025.101288. Research Gate.","DOI":"10.1016\/j.blre.2025.101288"},{"key":"891_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/jrms.JRMS_960_17","volume":"23","author":"RA Rusu","year":"2018","unstructured":"Rusu, R. A. et al. Chemotherapy-related infectious complications in patients with Hematologic malignancies. J. Res. Med. Sci. 23, 68 (2018).","journal-title":"J. Res. Med. Sci."},{"key":"891_CR13","first-page":"2020","volume":"12","author":"M Stanchina","year":"3225","unstructured":"Stanchina, M., Soong, D., Zheng-Lin, B., Watts, JM. & Taylor, J. Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development. Cancers (Basel) 12, 2020 (3225).","journal-title":"Cancers (Basel)"},{"key":"891_CR14","doi-asserted-by":"publisher","first-page":"896426","DOI":"10.3389\/fonc.2022.896426","volume":"12","author":"J Niu","year":"2022","unstructured":"Niu, J., Peng, D. & Liu, L. Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. Front Oncol. 12, 896426 (2022).","journal-title":"Front Oncol."},{"key":"891_CR15","doi-asserted-by":"publisher","first-page":"157264","DOI":"10.1016\/j.phymed.2025.157264","volume":"148","author":"C Zhuang","year":"2025","unstructured":"Zhuang, C. et al. Pathogenic mechanisms of cerebral ischemia and potential gut-brain axis-oriented therapeutic strategies. Phytomedicine 148, 157264 (2025).","journal-title":"Phytomedicine"},{"key":"891_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/jcm13020549","volume":"13","author":"R Rahm\u00e9\u201a","year":"2024","unstructured":"Rahm\u00e9\u201a R. & Braun, T. Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and\/or Relapsed Acute Myeloid Leukemia?. J. Clin. Med. 13, 549 (2024).","journal-title":"J. Clin. Med."},{"key":"891_CR17","doi-asserted-by":"publisher","first-page":"10255","DOI":"10.3390\/ijms251910255","volume":"25","author":"P Guevara-Ram\u00edrez","year":"2024","unstructured":"Guevara-Ram\u00edrez, P. et al. Gut Microbiota Disruption in Hematologic Cancer Therapy: Molecular Insights and Implications for Treatment Efficacy. Int. J. Mol. Sci. 25, 10255 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"891_CR18","doi-asserted-by":"publisher","first-page":"1586552","DOI":"10.3389\/fmed.2025.1586552","volume":"12","author":"M Li","year":"2025","unstructured":"Li, M. et al. Drug-tolerant persister cells in acute myeloid leukemia: pressing challenge and promising new strategies for treatment. Front. Med. (Lausanne) 12, 1586552 (2025).","journal-title":"Front. Med. (Lausanne)"},{"key":"891_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10238-025-01588-0","volume":"25","author":"A Raoufi","year":"2025","unstructured":"Raoufi, A. et al. Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets. Clin. Exp. Med. 25, 73 (2025).","journal-title":"Clin. Exp. Med."},{"key":"891_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06797-5","volume":"23","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan, H. et al. The microbiome in graft-versus-host disease: a tale of two ecosystems. J. Transl. Med. 23, 832 (2025).","journal-title":"J. Transl. Med."},{"key":"891_CR21","doi-asserted-by":"publisher","first-page":"104986","DOI":"10.1016\/j.cellimm.2025.104986","volume":"414","author":"I Ahmad","year":"2025","unstructured":"Ahmad, I. et al. Mesenchymal stem cell-derived exosomes (MSC-exosomes) in hematology: From mechanisms to clinical breakthroughs. Cell. Immunol. 414, 104986 (2025).","journal-title":"Cell. Immunol."},{"key":"891_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/cncr.33400","volume":"127","author":"CR D\u2019Angelo","year":"2021","unstructured":"D\u2019Angelo, C. R., Sudakaran, S. & Callander, N. S. Clinical effects and applications of the gut microbiome in hematologic malignancies. Cancer 127, 679\u2013687 (2021).","journal-title":"Cancer"},{"key":"891_CR23","doi-asserted-by":"publisher","first-page":"2428843","DOI":"10.1080\/21505594.2024.2428843","volume":"15","author":"Y Luo","year":"2024","unstructured":"Luo, Y. et al. Exploring the dynamics of gut microbiota, antibiotic resistance, and chemotherapy impact in acute leukemia patients: A comprehensive metagenomic analysis. Virulence 15, 2428843 (2024).","journal-title":"Virulence"},{"key":"891_CR24","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.3324\/haematol.2023.284138","volume":"109","author":"SA P\u00f6tgens","year":"2024","unstructured":"P\u00f6tgens, S. A. et al. Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia. Haematologica 109, 3194\u20133208 (2024).","journal-title":"Haematologica"},{"key":"891_CR25","doi-asserted-by":"publisher","first-page":"16431","DOI":"10.1002\/cam4.6283","volume":"12","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Alteration of gut microbiome and correlated amino acid metabolism are associated with acute myelocytic leukemia carcinogenesis. Cancer Med. 12, 16431\u201316443 (2023).","journal-title":"Cancer Med."},{"key":"891_CR26","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1002\/2211-5463.13193","volume":"11","author":"D Yu","year":"2021","unstructured":"Yu, D. et al. Profiling of gut microbial dysbiosis in adults with myeloid leukemia. FEBS Open Bio. 11, 2050\u20132059 (2021).","journal-title":"FEBS Open Bio."},{"key":"891_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30240-8","volume":"13","author":"R Wang","year":"2022","unstructured":"Wang, R. et al. Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate. Nat. Commun. 13, 2522 (2022).","journal-title":"Nat. Commun."},{"key":"891_CR28","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/bloodadvances.2024015571","volume":"9","author":"F Malard","year":"2025","unstructured":"Malard, F. et al. Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial. Blood Adv. 9, 3739\u20133749 (2025).","journal-title":"Blood Adv."},{"key":"891_CR29","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40487-024-00300-8","volume":"12","author":"Q Yang","year":"2024","unstructured":"Yang, Q. et al. Causal Relationship Between Gut Microbiota and Leukemia: Future Perspectives. Oncol. Ther. 12, 663\u2013683 (2024).","journal-title":"Oncol. Ther."},{"key":"891_CR30","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.apsb.2020.09.013","volume":"11","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharmaceutica Sin. B 11, 1789\u20131812 (2021).","journal-title":"Acta Pharmaceutica Sin. B"},{"key":"891_CR31","doi-asserted-by":"publisher","first-page":"1045497","DOI":"10.3389\/fmicb.2022.1045497","volume":"13","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y., Zhou, C. & Zhang, A. Gut microbiota in acute leukemia: current evidence and future directions. Front. Microbiol. 13, 1045497 (2022).","journal-title":"Front. Microbiol."},{"key":"891_CR32","doi-asserted-by":"publisher","first-page":"6031","DOI":"10.3390\/ijms24076031","volume":"24","author":"C Sandoval","year":"2023","unstructured":"Sandoval, C. et al. An updated overview of the role of CYP450 during xenobiotic metabolization in regulating the acute myeloid leukemia microenvironment. Int. J. Mol. Sci. 24, 6031 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"891_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40495-019-00200-w","volume":"5","author":"JL Dempsey","year":"2019","unstructured":"Dempsey, J. L. & Cui, J. Y. Microbiome is a functional modifier of P450 drug metabolism. Curr. Pharm. Rep. 5, 481\u2013490 (2019).","journal-title":"Curr. Pharm. Rep."},{"key":"891_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1039\/C7NP00063D","volume":"35","author":"A Greule","year":"2018","unstructured":"Greule, A. et al. Unrivalled diversity: the many roles and reactions of bacterial cytochromes P450 in secondary metabolism. Nat. Prod. Rep. 35, 757\u2013791 (2018).","journal-title":"Nat. Prod. Rep."},{"key":"891_CR35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2174\/1389200216888150915112039","volume":"16","author":"DW Edwardson","year":"2015","unstructured":"Edwardson, D. W. et al. Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines. Curr. Drug Metab. 16, 412\u2013426 (2015).","journal-title":"Curr. Drug Metab."},{"key":"891_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00068-21","volume":"6","author":"RA Blaustein","year":"2021","unstructured":"Blaustein, R. A., Seed, P. C. & Hartmann, E. M. Biotransformation of Doxorubicin Promotes Resilience in Simplified Intestinal Microbial Communities. mSphere 6, e0006821 (2021).","journal-title":"mSphere"},{"key":"891_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1021\/acsinfecdis.7b00166","volume":"4","author":"A Yan","year":"2018","unstructured":"Yan, A. et al. Transformation of the Anticancer Drug Doxorubicin in the Human Gut Microbiome. ACS Infect. Dis. 4, 68\u201376 (2018).","journal-title":"ACS Infect. Dis."},{"key":"891_CR38","doi-asserted-by":"publisher","first-page":"710945","DOI":"10.3389\/fcimb.2021.710945","volume":"11","author":"B Yue","year":"2021","unstructured":"Yue, B. et al. Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy. Front Cell Infect. Microbiol. 11, 710945 (2021).","journal-title":"Front Cell Infect. Microbiol."},{"key":"891_CR39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.gastro.2022.10.018","volume":"164","author":"D Chrysostomou","year":"2023","unstructured":"Chrysostomou, D. et al. Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. Gastroenterology 164, 198\u2013213 (2023).","journal-title":"Gastroenterology"},{"key":"891_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2019.03.002","volume":"199","author":"AN Chamseddine","year":"2019","unstructured":"Chamseddine, A. N. et al. Intestinal bacterial \u03b2-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. Pharm. Ther. 199, 1\u201315 (2019).","journal-title":"Pharm. Ther."},{"key":"891_CR41","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3389\/fmicb.2019.02305","volume":"10","author":"MA Engevik","year":"2019","unstructured":"Engevik, M. A. et al. Microbial metabolic capacity for intestinal folate production and modulation of host folate receptors. Front. Microbiol. 10, 2305 (2019).","journal-title":"Front. Microbiol."},{"key":"891_CR42","doi-asserted-by":"publisher","first-page":"1559033","DOI":"10.3389\/fmicb.2025.1559033","volume":"16","author":"S An","year":"2025","unstructured":"An, S. et al. Significant changes in gut microbiota and SCFAs among patients with newly diagnosed acute myeloid leukemia. Front. Microbiol. 16, 1559033 (2025).","journal-title":"Front. Microbiol"},{"key":"891_CR43","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1128\/AAC.44.11.3210-3212.2000","volume":"44","author":"SJ Kopytek","year":"2000","unstructured":"Kopytek, S. J. et al. Resistance to methotrexate due to AcrAB-dependent export from Escherichia coli. Antimicrobial agents Chemother. 44, 3210\u20133212 (2000).","journal-title":"Antimicrobial agents Chemother."},{"key":"891_CR44","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.3390\/microorganisms10122382","volume":"10","author":"RMRA Effendi","year":"2022","unstructured":"Effendi, R. M. R. A. et al. Akkermansia muciniphila and Faecalibacterium prausnitzii in Immune-Related Diseases. Microorganisms 10, 2382 (2022).","journal-title":"Microorganisms"},{"key":"891_CR45","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.clnu.2023.09.021","volume":"42","author":"SA P\u00f6tgens","year":"2023","unstructured":"P\u00f6tgens, S. A. et al. Gut microbiota alterations induced by intensive chemotherapy in acute myeloid leukaemia patients are associated with gut barrier dysfunction and body weight loss. Clin. Nutr. 42, 2214\u20132228 (2023).","journal-title":"Clin. Nutr."},{"key":"891_CR46","doi-asserted-by":"publisher","first-page":"e120974","DOI":"10.1172\/jci.insight.120974","volume":"3","author":"HA Knaus","year":"2018","unstructured":"Knaus, H. A. et al. Signatures of CD8+T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight 3, e120974 (2018).","journal-title":"JCI Insight"},{"key":"891_CR47","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14744\/ejmo.2023.35138","volume":"2023","author":"A Zahran","year":"2023","unstructured":"Zahran, A. et al. Disturbed Expression of Memory T-Cell Subsets Could Alter the Outcomes in Adult Acute Myeloid Leukemia. Eurasia. J. Med. Oncol. 2023, 362\u2013370 (2023).","journal-title":"Eurasia. J. Med. Oncol."},{"key":"891_CR48","doi-asserted-by":"publisher","first-page":"10026","DOI":"10.1200\/JCO.2025.43.16_suppl.10026","volume":"43","author":"O Gordon","year":"2025","unstructured":"Gordon, O. et al. Gut microbiome changes in pediatric AML and association with event free survival. J. Clin. Oncol. 43, 10026\u201310026 (2025).","journal-title":"J. Clin. Oncol."},{"key":"891_CR49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/prd.12426","volume":"89","author":"T Alon-Maimon","year":"2022","unstructured":"Alon-Maimon, T., Mandelboim, O. & Bachrach, G. Fusobacterium nucleatum and cancer. Periodontology 2000 89, 166\u2013180 (2022).","journal-title":"Periodontology 2000"},{"key":"891_CR50","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","volume":"170","author":"T Yu","year":"2017","unstructured":"Yu, T. et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell 170, 548\u2013563.e16 (2017).","journal-title":"Cell"},{"key":"891_CR51","doi-asserted-by":"publisher","first-page":"e1012302","DOI":"10.1371\/journal.ppat.1012302","volume":"20","author":"FE Aggor","year":"2024","unstructured":"Aggor, F. E. et al. Combinatorial actions of IL-22 and IL-17 drive optimal immunity to oral candidiasis through SPRRs. PLoS Pathog. 20, e1012302 (2024).","journal-title":"PLoS Pathog."},{"key":"891_CR52","doi-asserted-by":"publisher","first-page":"21519","DOI":"10.1073\/pnas.2003004117","volume":"117","author":"DN Powell","year":"2020","unstructured":"Powell, D. N. et al. Indoles from the commensal microbiota act via the AHR and IL-10 to tune the cellular composition of the colonic epithelium during aging. Proc. Natl. Acad. Sci. 117, 21519\u201321526 (2020).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"891_CR53","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.immuni.2013.08.003","volume":"39","author":"T Zelante","year":"2013","unstructured":"Zelante, T. et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39, 372\u2013385 (2013).","journal-title":"Immunity"},{"key":"891_CR54","doi-asserted-by":"publisher","first-page":"647398","DOI":"10.3389\/fimmu.2021.647398","volume":"12","author":"EM Walker","year":"2021","unstructured":"Walker, E. M. et al. Dysregulation of IL-17\/IL-22 effector functions in blood and gut mucosal gamma delta T cells correlates with increase in circulating leaky gut and inflammatory markers during cART-treated chronic SIV infection in macaques. Front. Immunol. 12, 647398 (2021).","journal-title":"Front. Immunol."},{"key":"891_CR55","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4014\/jmb.2301.01031","volume":"33","author":"M-Y Son","year":"2023","unstructured":"Son, M.-Y. & Cho, H.-S. Anticancer effects of gut microbiota-derived short-chain fatty acids in cancers. J. Microbiol. Biotechnol. 33, 849 (2023).","journal-title":"J. Microbiol. Biotechnol."},{"key":"891_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-5-71","volume":"5","author":"J Chen","year":"2006","unstructured":"Chen, J. et al. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt\/protein kinase B. Mol. Cancer 5, 71 (2006).","journal-title":"Mol. Cancer"},{"key":"891_CR57","doi-asserted-by":"publisher","first-page":"e75908","DOI":"10.7554\/eLife.75908","volume":"11","author":"N Vilaplana-Lopera","year":"2022","unstructured":"Vilaplana-Lopera, N. et al. Crosstalk between AML and stromal cells triggers acetate secretion through the metabolic rewiring of stromal cells. Elife 11, e75908 (2022).","journal-title":"Elife"},{"key":"891_CR58","doi-asserted-by":"publisher","first-page":"114988","DOI":"10.1016\/j.celrep.2024.114988","volume":"43","author":"SI Hlavaty","year":"2024","unstructured":"Hlavaty, S. I. et al. ACSS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis. Cell Rep. 43, 114988 (2024).","journal-title":"Cell Rep."},{"key":"891_CR59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fcimb.2018.00013","volume":"8","author":"J Gao","year":"2018","unstructured":"Gao, J. et al. Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism. Front Cell Infect. Microbiol. 8, 13 (2018).","journal-title":"Front Cell Infect. Microbiol."},{"key":"891_CR60","doi-asserted-by":"publisher","first-page":"117864692412482","DOI":"10.1177\/11786469241248287","volume":"17","author":"BS Summers","year":"2024","unstructured":"Summers, B. S. et al. A Review of the Evidence for Tryptophan and the Kynurenine Pathway as a Regulator of Stem Cell Niches in Health and Disease. Int. J. Tryptophan. Res. 17, 11786469241248287 (2024).","journal-title":"Int. J. Tryptophan. Res."},{"key":"891_CR61","doi-asserted-by":"publisher","first-page":"636081","DOI":"10.3389\/fimmu.2021.636081","volume":"12","author":"M Kim","year":"2021","unstructured":"Kim, M. & Tomek, P. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO. Front Immunol. 12, 636081 (2021).","journal-title":"Front Immunol."},{"key":"891_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05470-4","volume":"9","author":"HM Roager","year":"2018","unstructured":"Roager, H. M. & Licht, T. R. Microbial tryptophan catabolites in health and disease. Nat. Commun. 9, 3294 (2018).","journal-title":"Nat. Commun."},{"key":"891_CR63","doi-asserted-by":"publisher","first-page":"1256769","DOI":"10.3389\/fonc.2023.1256769","volume":"13","author":"RA Le\u00f3n-Letelier","year":"2023","unstructured":"Le\u00f3n-Letelier, R. A. et al. The kynurenine pathway presents multi-faceted metabolic vulnerabilities in cancer. Front Oncol. 13, 1256769 (2023).","journal-title":"Front Oncol."},{"key":"891_CR64","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.tips.2023.04.006","volume":"44","author":"TW Stone","year":"2023","unstructured":"Stone, T. W. & Williams, R. O. Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends Pharm. Sci. 44, 442\u2013456 (2023).","journal-title":"Trends Pharm. Sci."},{"key":"891_CR65","doi-asserted-by":"publisher","first-page":"1355387","DOI":"10.3389\/fendo.2024.1355387","volume":"15","author":"Y Shi","year":"2024","unstructured":"Shi, Y., Li, X. & Zhang, J. Systematic review on the role of the gut microbiota in tumors and their treatment. Front. Endocrinol. 15, 1355387 (2024).","journal-title":"Front. Endocrinol."},{"key":"891_CR66","doi-asserted-by":"publisher","first-page":"1514872","DOI":"10.3389\/fonc.2025.1514872","volume":"15","author":"M Kouhzad","year":"2025","unstructured":"Kouhzad, M. et al. Carcinogenic and anticancer activities of microbiota-derived secondary bile acids. Front. Oncol. 15, 1514872 (2025).","journal-title":"Front. Oncol."},{"key":"891_CR67","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.18632\/oncotarget.3545","volume":"6","author":"J Zhou","year":"2015","unstructured":"Zhou, J., Ching, Y. Q. & Chng, W.-J. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target. Oncotarget 6, 5490 (2015).","journal-title":"Oncotarget"},{"key":"891_CR68","doi-asserted-by":"publisher","first-page":"e93019","DOI":"10.7554\/eLife.93019","volume":"13","author":"K Nuno","year":"2024","unstructured":"Nuno, K. et al. Convergent epigenetic evolution drives relapse in acute myeloid leukemia. Elife 13, e93019 (2024).","journal-title":"Elife"},{"key":"891_CR69","doi-asserted-by":"publisher","first-page":"2485S","DOI":"10.1093\/jn\/133.7.2485S","volume":"133","author":"JR Davie","year":"2003","unstructured":"Davie, J. R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 133, 2485S\u20132493S (2003).","journal-title":"J. Nutr."},{"key":"891_CR70","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1006\/excr.2002.5548","volume":"277","author":"M Rahmani","year":"2002","unstructured":"Rahmani, M., Dai, Y. & Grant, S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-\u03b1-mediated process. Exp. cell Res. 277, 31\u201347 (2002).","journal-title":"Exp. cell Res."},{"key":"891_CR71","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41568-023-00584-4","volume":"23","author":"I Peppas","year":"2023","unstructured":"Peppas, I. et al. Gut microbiome immaturity and childhood acute lymphoblastic leukaemia. Nat. Rev. Cancer 23, 565\u2013576 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"891_CR72","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach, P. & Trumpp, A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica 108, 353 (2023).","journal-title":"Haematologica"},{"key":"891_CR73","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3324\/haematol.2024.286018","volume":"110","author":"Y Morgenstern","year":"2024","unstructured":"Morgenstern, Y. et al. Acute myeloid leukemia drug-tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing. Haematologica 110, 893 (2024).","journal-title":"Haematologica"},{"key":"891_CR74","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/hon.3076","volume":"41","author":"FA Lagunas-Rangel","year":"2023","unstructured":"Lagunas-Rangel, F. A. DNA damage accumulation and repair defects in FLT3-ITD acute myeloid leukemia: implications for clonal evolution and disease progression. Hematological Oncol. 41, 26\u201338 (2023).","journal-title":"Hematological Oncol."},{"key":"891_CR75","doi-asserted-by":"crossref","unstructured":"Tewari, N. and P. Dey, Navigating Commensal Dysbiosis:Gastrointestinal Host-Pathogen Interplay in Orchestrating Opportunistic Infections. Microbiol. Res. 127832 (2024).","DOI":"10.1016\/j.micres.2024.127832"},{"key":"891_CR76","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13756-023-01269-1","volume":"12","author":"LP Liu","year":"2023","unstructured":"Liu, L. P. et al. High risk of bloodstream infection of carbapenem-resistant enterobacteriaceae carriers in neutropenic children with hematological diseases. Antimicrob. Resist Infect. Control 12, 66 (2023).","journal-title":"Antimicrob. Resist Infect. Control"},{"key":"891_CR77","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/14787210.2025.2487149","volume":"23","author":"C Bo\u015fnak","year":"2025","unstructured":"Bo\u015fnak, C. & Akova, M. Febrile neutropenia management in high-risk neutropenic patients: a narrative review on antibiotic prophylaxis and empirical treatment. Expert Rev. Anti Infect. Ther. 23, 327\u2013341 (2025).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"891_CR78","doi-asserted-by":"publisher","first-page":"1373846","DOI":"10.3389\/fcimb.2024.1373846","volume":"14","author":"L Shani","year":"2024","unstructured":"Shani, L. & Nissan, I. Editorial: Antibiotics overuse as the driving force behind antimicrobial resistance. Front Cell Infect. Microbiol. 14, 1373846 (2024).","journal-title":"Front Cell Infect. Microbiol."},{"key":"891_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-023-00554-6","volume":"22","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Prevalence and factors associated with carbapenem-resistant Enterobacterales (CRE) infection among hematological malignancies patients with CRE intestinal colonization. Ann. Clin. Microbiol. Antimicrobials 22, 3 (2023).","journal-title":"Ann. Clin. Microbiol. Antimicrobials"},{"key":"891_CR80","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.3390\/curroncol29090491","volume":"29","author":"RJ Stubbins","year":"2022","unstructured":"Stubbins, R. J. et al. Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology. Curr. Oncol. 29, 6245\u20136259 (2022).","journal-title":"Curr. Oncol."},{"key":"891_CR81","doi-asserted-by":"publisher","first-page":"1468645","DOI":"10.3389\/fcimb.2024.1468645","volume":"14","author":"IC V\u0103c\u0103rean-Trandafir","year":"2025","unstructured":"V\u0103c\u0103rean-Trandafir, I. C. et al. Impact of antibiotic prophylaxis on gut microbiota in colorectal surgery: insights from an Eastern European stewardship study. Front. Cell. Infect. Microbiol. 14, 1468645 (2025).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"891_CR82","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/cid\/ciz777","volume":"71","author":"JR Galloway-Pe\u00f1a","year":"2020","unstructured":"Galloway-Pe\u00f1a, J. R. et al. Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clin. Infect. Dis. 71, 63\u201371 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"891_CR83","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1240537","volume":"342","author":"S Viaud","year":"2013","unstructured":"Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971 (2013).","journal-title":"Science"},{"key":"891_CR84","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pedn.2023.02.002","volume":"70","author":"C Johnson","year":"2023","unstructured":"Johnson, C. et al. Quality improvement: Antimicrobial stewardship in pediatric primary care. J. Pediatr. Nurs. 70, 54\u201360 (2023).","journal-title":"J. Pediatr. Nurs."},{"key":"891_CR85","doi-asserted-by":"publisher","first-page":"1427185","DOI":"10.3389\/fped.2024.1427185","volume":"12","author":"M \u0160imiakov\u00e1","year":"2024","unstructured":"\u0160imiakov\u00e1, M. & Bielik, V. The pros and cons of probiotic use in pediatric oncology patients following treatment for acute lymphoblastic leukemia. Front Pediatr. 12, 1427185 (2024).","journal-title":"Front Pediatr."},{"key":"891_CR86","doi-asserted-by":"publisher","first-page":"1423838","DOI":"10.3389\/fmicb.2024.1423838","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Advancements in the impact of human microbiota and probiotics on leukemia. Front Microbiol. 15, 1423838 (2024).","journal-title":"Front Microbiol."},{"key":"891_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.30699\/mci.6.3.552-1","volume":"6","author":"M Azizpour Maghvan","year":"2022","unstructured":"Azizpour Maghvan, M., Jafari, P. J. & Anushiravani, A. A. Investigating the Influence of Probiotic Bacteria on Anemia and White Blood Cells Count in Cancer Patients Undergoing Chemotherapy and Radiation Therapy. Multidiscip. Cancer Investig. 6, 1\u20136 (2022).","journal-title":"Multidiscip. Cancer Investig."},{"key":"891_CR88","doi-asserted-by":"publisher","first-page":"1575798","DOI":"10.3389\/fcimb.2025.1575798","volume":"15","author":"W Han","year":"2025","unstructured":"Han, W., Xiong, N. & Huang, L. Probiotics and nanoparticle-mediated nutrient delivery in the management of transfusion-supported diseases. Front. Cell. Infect. Microbiol. 15, 1575798 (2025).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"891_CR89","volume":"14","author":"MS Alabdaljabar","year":"2022","unstructured":"Alabdaljabar, M. S. et al. Restoration of the Original Inhabitants: A Systematic Review on Fecal Microbiota Transplantation for Graft-Versus-Host Disease. Cureus 14, e23873 (2022).","journal-title":"Cureus"},{"key":"891_CR90","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fimmu.2024.1439176","volume":"15","author":"M Karimi","year":"2024","unstructured":"Karimi, M. et al. Safety and efficacy of fecal microbiota transplantation (FMT) as a modern adjuvant therapy in various diseases and disorders: a comprehensive literature review. Front. Immunol. 15, 2024 (2024).","journal-title":"Front. Immunol."},{"key":"891_CR91","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood-2024-202112","volume":"144","author":"A Rashidi","year":"2024","unstructured":"Rashidi, A. et al. Fecal Microbiota Transplantation to Prevent Acute Graft-Versus-Host Disease: First Pre-Planned Interim Analysis of a Randomized Trial. Blood 144, 2149\u20132149 (2024).","journal-title":"Blood"},{"key":"891_CR92","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000538303","volume":"40","author":"D Weber","year":"2024","unstructured":"Weber, D. et al. Fecal Microbiota Transfer in Acute Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation. Visc. Med. 40, 210\u2013216 (2024).","journal-title":"Visc. Med."},{"key":"891_CR93","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00277-024-05952-0","volume":"104","author":"J Kujawska","year":"2025","unstructured":"Kujawska, J., Zeiser, R. & Gil, L. Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease. Ann. Hematol. 104, 855\u2013865 (2025).","journal-title":"Ann. Hematol."},{"key":"891_CR94","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1182\/bloodadvances.2024012556","volume":"8","author":"Z DeFilipp","year":"2024","unstructured":"DeFilipp, Z. et al. Third-party fecal microbiota transplantation for high-risk treatment-na\u00efve acute GVHD of the lower GI tract. Blood Adv. 8, 2074\u20132084 (2024).","journal-title":"Blood Adv."},{"key":"891_CR95","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/S1470-2045(18)30952-5","volume":"20","author":"JL McQuade","year":"2019","unstructured":"McQuade, J. L. et al. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 20, e77\u2013e91 (2019).","journal-title":"Lancet Oncol."},{"key":"891_CR96","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40164-022-00350-6","volume":"11","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD. Exp. Hematol. Oncol. 11, 96 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"891_CR97","doi-asserted-by":"publisher","first-page":"E461","DOI":"10.1002\/ajh.26365","volume":"96","author":"J Bili\u0144ski","year":"2021","unstructured":"Bili\u0144ski, J. et al. Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory\/dependent acute, gastrointestinal graft-versus-host disease: a case series. Am. J. Hematol. 96, E461\u2013E463. (2021).","journal-title":"Am. J. Hematol."},{"key":"891_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56375-y","volume":"16","author":"S Reddi","year":"2025","unstructured":"Reddi, S. et al. Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect. Nat. Commun. 16, 1034 (2025).","journal-title":"Nat. Commun."},{"key":"891_CR99","doi-asserted-by":"publisher","first-page":"2003542","DOI":"10.1002\/advs.202003542","volume":"8","author":"R Zhu","year":"2021","unstructured":"Zhu, R. et al. Gut microbiota: influence on carcinogenesis and modulation strategies by drug delivery systems to improve cancer therapy. Adv. Sci. 8, 2003542 (2021).","journal-title":"Adv. Sci."},{"key":"891_CR100","first-page":"102111","volume":"62","author":"F Malard","year":"2023","unstructured":"Malard, F. et al. Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial. E Clinical Medicine 62, 102111 (2023).","journal-title":"E Clinical Medicine"},{"key":"891_CR101","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cgh.2024.10.001","volume":"23","author":"MV B\u00e9nard","year":"2025","unstructured":"B\u00e9nard, M. V. et al. Gut Microbiota Features in Relation to Fecal Microbiota Transplantation Outcome in Ulcerative Colitis: A Systematic Review and Meta-Analysis. Clin. Gastroenterol. Hepatol. 23, 1719\u20131736 (2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"891_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-02046-5","volume":"29","author":"S-W Lo","year":"2024","unstructured":"Lo, S.-W. et al. Clinical efficacy and safety of faecal microbiota transplantation in the treatment of irritable bowel syndrome: a systematic review, meta-analysis and trial sequential analysis. Eur. J. Med. Res. 29, 464 (2024).","journal-title":"Eur. J. Med. Res."},{"key":"891_CR103","first-page":"e23873","volume":"14","author":"M Alabdaljabar","year":"2022","unstructured":"Alabdaljabar, M. et al. Restoration of the original inhabitants: a systematic review on fecal microbiota transplantation for graft-versus-host disease. Cureus 14, e23873 (2022).","journal-title":"Cureus"},{"key":"891_CR104","first-page":"903.e1","volume":"30","author":"SR Solomon","year":"2024","unstructured":"Solomon, S. R. et al. Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation. Transpl. Cell Ther. 30, 903.e1\u2013903.e9 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"891_CR105","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.4103\/jcrt.jcrt_33_24","volume":"20","author":"Z Guo","year":"2024","unstructured":"Guo, Z. et al. The role of fecal microbiota transplantation in the treatment of acute graft-versus-host disease. J. Cancer Res Ther. 20, 1964\u20131973 (2024).","journal-title":"J. Cancer Res Ther."},{"key":"891_CR106","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1200\/JCO.2019.37.15_suppl.7015","volume":"37","author":"J Peled","year":"2019","unstructured":"Peled, J. et al. Inferior survival after microbiota injury: A multicenter allo-HCT study. J. Clin. Oncol. 37, 7015\u20137015 (2019).","journal-title":"J. Clin. Oncol."},{"key":"891_CR107","doi-asserted-by":"publisher","first-page":"eabq4006","DOI":"10.1126\/scitranslmed.abq4006","volume":"15","author":"TM Halsey","year":"2023","unstructured":"Halsey, T. M. et al. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor\u2013induced colitis. Sci. Transl. Med. 15, eabq4006 (2023).","journal-title":"Sci. Transl. Med."},{"key":"891_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-019-0189-9","volume":"13","author":"L He","year":"2019","unstructured":"He, L. et al. Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy. J. Biol. Eng. 13, 58 (2019).","journal-title":"J. Biol. Eng."},{"key":"891_CR109","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00253-021-11646-8","volume":"106","author":"MK Yadav","year":"2022","unstructured":"Yadav, M. K. et al. Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics. Appl. Microbiol. Biotechnol. 106, 505\u2013521 (2022).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"891_CR110","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/nu15020291","volume":"15","author":"L Ma","year":"2023","unstructured":"Ma, L., Tu, H. & Chen, T. Postbiotics in human health: a narrative review. Nutrients 15, 291 (2023).","journal-title":"Nutrients"},{"key":"891_CR111","doi-asserted-by":"publisher","first-page":"1394379","DOI":"10.1155\/2018\/1394379","volume":"2018","author":"O Shogbesan","year":"2018","unstructured":"Shogbesan, O. et al. A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised Patients. Can. J. Gastroenterol. Hepatol. 2018, 1394379 (2018).","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"891_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-024-04955-7","volume":"24","author":"B Yang","year":"2024","unstructured":"Yang, B., Li, W. & Shi, J. Preventive effect of probiotics on oral mucositis induced by anticancer therapy: a systematic review and meta-analysis of randomized controlled trials. BMC Oral. Health 24, 1159 (2024).","journal-title":"BMC Oral. Health"},{"key":"891_CR113","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12876-025-03914-y","volume":"25","author":"R Yang","year":"2025","unstructured":"Yang, R. et al. Evaluation of the efficacy of probiotics in the chemoradiotherapy of colorectal cancer: a meta-analysis of Randomized Controlled Trials. BMC Gastroenterol. 25, 312 (2025).","journal-title":"BMC Gastroenterol."},{"key":"891_CR114","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3390\/microorganisms11071775","volume":"11","author":"A Martyniak","year":"2023","unstructured":"Martyniak, A. et al. Prevention and health benefits of prebiotics, probiotics and postbiotics in acute lymphoblastic leukemia. Microorganisms 11, 1775 (2023).","journal-title":"Microorganisms"},{"key":"891_CR115","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/MPH.0000000000001497","volume":"41","author":"J Reyna-Figueroa","year":"2019","unstructured":"Reyna-Figueroa, J. et al. Probiotic supplementation decreases chemotherapy-induced gastrointestinal side effects in patients with acute leukemia. J. Pediatr. Hematol. Oncol. 41, 468\u2013472 (2019).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"891_CR116","doi-asserted-by":"publisher","first-page":"e37971","DOI":"10.1371\/journal.pone.0037971","volume":"7","author":"LB Bindels","year":"2012","unstructured":"Bindels, L. B. et al. Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model. PloS one 7, e37971 (2012).","journal-title":"PloS one"},{"key":"891_CR117","first-page":"389","volume":"24","author":"SS Sharifzadeh","year":"2023","unstructured":"Sharifzadeh, S. S. et al. Antifungal effect of probiotic Lactobacillus casei on drug-resistant oral Candida albicans isolated from patients with hematological malignancy: an in vitro study. J. Dent. 24, 389 (2023).","journal-title":"J. Dent."},{"key":"891_CR118","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3390\/pharmaceutics14081705","volume":"14","author":"F D\u2019Amico","year":"2022","unstructured":"D\u2019Amico, F. et al. Oral lactoferrin supplementation during induction chemotherapy promotes gut microbiome eubiosis in pediatric patients with hematologic malignancies. Pharmaceutics 14, 1705 (2022).","journal-title":"Pharmaceutics"},{"key":"891_CR119","doi-asserted-by":"crossref","unstructured":"Su, M. et al. Astragalus improves intestinal barrier function and immunity by acting on intestinal microbiota to treat T2DM: a research review. Front. Immunol. 14, (2023).","DOI":"10.3389\/fimmu.2023.1243834"},{"key":"891_CR120","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3389\/fmicb.2019.00731","volume":"10","author":"Y Meng","year":"2019","unstructured":"Meng, Y. et al. Lactobacillus plantarum KLDS1. 0318 ameliorates impaired intestinal immunity and metabolic disorders in cyclophosphamide-treated mice. Front. Microbiol. 10, 731 (2019).","journal-title":"Front. Microbiol."},{"key":"891_CR121","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1039\/C5FO01516B","volume":"7","author":"J-H Xie","year":"2016","unstructured":"Xie, J.-H. et al. Lactobacillus plantarum NCU116 attenuates cyclophosphamide-induced intestinal mucosal injury, metabolism and intestinal microbiota disorders in mice. Food Funct. 7, 1584\u20131592 (2016).","journal-title":"Food Funct."},{"key":"891_CR122","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12602-022-10015-9","volume":"16","author":"Y Song","year":"2024","unstructured":"Song, Y. et al. Lactiplantibacillus plantarum DLPT4 protects against cyclophosphamide-induced immunosuppression in mice by regulating immune response and intestinal flora. Probiotics Antimicrobial Proteins 16, 321\u2013333 (2024).","journal-title":"Probiotics Antimicrobial Proteins"},{"key":"891_CR123","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12185-014-1650-7","volume":"100","author":"Y Ishihara","year":"2014","unstructured":"Ishihara, Y. et al. Severe oral infection due to Lactobacillus rhamnosus during induction chemotherapy for acute myeloid leukemia. Int. J. Hematol. 100, 607\u2013610 (2014).","journal-title":"Int. J. Hematol."},{"key":"891_CR124","doi-asserted-by":"publisher","first-page":"1800897","DOI":"10.1080\/19490976.2020.1800897","volume":"12","author":"T Hueso","year":"2020","unstructured":"Hueso, T. et al. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening. Gut microbes 12, 1800897 (2020).","journal-title":"Gut microbes"},{"key":"891_CR125","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00280-021-04385-0","volume":"89","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota. Cancer Chemother. Pharmacol. 89, 243\u2013253 (2022).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"891_CR126","first-page":"2023","volume":"14","author":"F Chen","year":"2023","unstructured":"Chen, F. et al. Effects of Litsea cubeba essential oil on growth performance, blood antioxidation, immune function, apparent digestibility of nutrients, and fecal microflora of pigs. Front. Pharmacol. 14, 2023 (2023).","journal-title":"Front. Pharmacol."},{"key":"891_CR127","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1002\/ptr.70067","volume":"39","author":"P Guo","year":"2025","unstructured":"Guo, P. et al. Zingibroside R1 Isolated From Achyranthes bidentata Blume Ameliorates LPS\/D-GalN-Induced Liver Injury by Regulating Succinic Acid Metabolism via the Gut Microbiota. Phytother. Res. 39, 4520\u20134534 (2025).","journal-title":"Phytother. Res."},{"key":"891_CR128","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3923\/ijp.2023.632.641","volume":"19","author":"Q Su","year":"2023","unstructured":"Su, Q. et al. Dihydroartemisinin Increases the Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via the Nrf2\/HO-1 Anti-Oxidant Signaling Pathway. Int. J. Pharmacol. 19, 632\u2013641 (2023).","journal-title":"Int. J. Pharmacol."},{"key":"891_CR129","first-page":"1747","volume":"129","author":"S-R Wu","year":"2017","unstructured":"Wu, S.-R. & Reddy, P. Tissue tolerance: a distinct concept to control acute GVHD severity. Blood, J. Am. Soc. Hematol. 129, 1747\u20131752 (2017).","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"891_CR130","doi-asserted-by":"publisher","first-page":"2178805","DOI":"10.1080\/19490976.2023.2178805","volume":"15","author":"YF van Lier","year":"2023","unstructured":"van Lier, Y. F. et al. Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease. Gut Microbes 15, 2178805 (2023).","journal-title":"Gut Microbes"},{"key":"891_CR131","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41419-022-04763-3","volume":"13","author":"O ElMokh","year":"2022","unstructured":"ElMokh, O. et al. Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia. Cell Death Dis. 13, 320 (2022).","journal-title":"Cell Death Dis."},{"key":"891_CR132","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3390\/biomedicines13071761","volume":"13","author":"A Nowicka","year":"2025","unstructured":"Nowicka, A. et al. Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML\u2014One Step Closer to Personalized Medicine. Biomedicines 13, 1761 (2025).","journal-title":"Biomedicines"},{"key":"891_CR133","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10123-022-00272-7","volume":"26","author":"HT Teker","year":"2023","unstructured":"Teker, H. T. & Ceylani, T. Intermittent fasting supports the balance of the gut microbiota composition. Int. Microbiol. 26, 51\u201357 (2023).","journal-title":"Int. Microbiol."},{"key":"891_CR134","doi-asserted-by":"publisher","first-page":"e189423f","DOI":"10.1097\/01.HS9.0000974040.18942.3f","volume":"7","author":"ML Cagigas","year":"2023","unstructured":"Cagigas, M. L. et al. PB1796: ADMINISTRATION OF A KETOGENIC DIET FOR CHEMOTHERAPY PROTECTION IN ACUTE LEUKEMIA PATIENTS: IS IT FEASIBLE, SAFE, AND VALUABLE? PRELIMINARY RESULTS OF THE RANDOMIZED CONTROLLED TRIAL LEU-KETO STUDY. HemaSphere 7, e189423f (2023).","journal-title":"HemaSphere"},{"key":"891_CR135","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2024-208913","volume":"144","author":"S Liu","year":"2024","unstructured":"Liu, S. et al. Ketogenic diet enhances CAR T cell antitumor function via \u03b2-hydroxybutyrate. Blood 144, 4 (2024).","journal-title":"Blood"},{"key":"891_CR136","doi-asserted-by":"publisher","first-page":"5870","DOI":"10.3390\/cancers15245870","volume":"15","author":"R Buono","year":"2023","unstructured":"Buono, R. et al. Fasting-mimicking diet inhibits autophagy and synergizes with chemotherapy to promote T-cell-dependent leukemia-free survival. Cancers 15, 5870 (2023).","journal-title":"Cancers"},{"key":"891_CR137","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nm.4252","volume":"23","author":"Z Lu","year":"2017","unstructured":"Lu, Z. et al. Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. Nat. Med. 23, 79\u201390 (2017).","journal-title":"Nat. Med."},{"key":"891_CR138","doi-asserted-by":"publisher","first-page":"e814s","DOI":"10.6061\/clinics\/2018\/e814s","volume":"73","author":"F Antunes","year":"2018","unstructured":"Antunes, F. et al. Autophagy and intermittent fasting: the connection for cancer therapy? Clinics 73, e814s (2018).","journal-title":"Clinics"},{"key":"891_CR139","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/nu11040719","volume":"11","author":"A Paoli","year":"2019","unstructured":"Paoli, A. et al. The influence of meal frequency and timing on health in humans: the role of fasting. Nutrients 11, 719 (2019).","journal-title":"Nutrients"},{"key":"891_CR140","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03498-1","volume":"20","author":"D Xu","year":"2022","unstructured":"Xu, D. et al. Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation. J. Transl. Med. 20, 300 (2022).","journal-title":"J. Transl. Med."},{"key":"891_CR141","doi-asserted-by":"publisher","first-page":"2281017","DOI":"10.1080\/19490976.2023.2281017","volume":"15","author":"K Ka\u017amierczak-Siedlecka","year":"2023","unstructured":"Ka\u017amierczak-Siedlecka, K. et al. Pharmacomicrobiomics of cell-cycle specific anti-cancer drugs\u2013is it a new perspective for personalized treatment of cancer patients? Gut microbes 15, 2281017 (2023).","journal-title":"Gut microbes"},{"key":"891_CR142","doi-asserted-by":"publisher","first-page":"103320","DOI":"10.1016\/j.transci.2021.103320","volume":"61","author":"R Ciftciler","year":"2022","unstructured":"Ciftciler, R. & Ciftciler, A. E. The importance of microbiota in hematology. Transfus. Apheresis Sci. 61, 103320 (2022).","journal-title":"Transfus. Apheresis Sci."},{"key":"891_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-023-00745-5","volume":"18","author":"E Hu","year":"2023","unstructured":"Hu, E. et al. A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example. Chin. Med. 18, 40 (2023).","journal-title":"Chin. Med."},{"key":"891_CR144","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1240537","volume":"342","author":"S Viaud","year":"2013","unstructured":"Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. science 342, 971\u2013976 (2013).","journal-title":"science"},{"key":"891_CR145","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1126\/science.aax0701","volume":"369","author":"A Fluckiger","year":"2020","unstructured":"Fluckiger, A. et al. Cross-reactivity between tumor MHC class I\u2013restricted antigens and an enterococcal bacteriophage. Science 369, 936\u2013942 (2020).","journal-title":"Science"},{"key":"891_CR146","doi-asserted-by":"publisher","first-page":"i6","DOI":"10.1093\/jac\/dky530","volume":"74","author":"AA Bhalodi","year":"2019","unstructured":"Bhalodi, A. A. et al. Impact of antimicrobial therapy on the gut microbiome. J. Antimicrobial Chemother. 74, i6\u2013i15 (2019).","journal-title":"J. Antimicrobial Chemother."},{"key":"891_CR147","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-018-0483-7","volume":"6","author":"C Panebianco","year":"2018","unstructured":"Panebianco, C., Andriulli, A. & Pazienza, V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 6, 92 (2018).","journal-title":"Microbiome"},{"key":"891_CR148","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/bph.16020","volume":"180","author":"J Meng","year":"2023","unstructured":"Meng, J. et al. Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model. Br. J. Pharmacol. 180, 1362\u20131378 (2023).","journal-title":"Br. J. Pharmacol."},{"key":"891_CR149","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1126\/science.1191175","volume":"330","author":"BD Wallace","year":"2010","unstructured":"Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831\u2013835 (2010).","journal-title":"Science"},{"key":"891_CR150","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1124\/mol.113.085852","volume":"84","author":"AB Roberts","year":"2013","unstructured":"Roberts, A. B. et al. Molecular insights into microbial \u03b2-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol. Pharm. 84, 208\u2013217 (2013).","journal-title":"Mol. Pharm."},{"key":"891_CR151","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1111\/febs.16945","volume":"290","author":"T Inamoto","year":"2023","unstructured":"Inamoto, T. et al. Short-chain fatty acids stimulate dendrite elongation in dendritic cells by inhibiting histone deacetylase. Febs j. 290, 5794\u20135810 (2023).","journal-title":"Febs j."},{"key":"891_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1921927","volume":"13","author":"D Radojevi\u0107","year":"2021","unstructured":"Radojevi\u0107, D. et al. Fecal microbiota composition associates with the capacity of human peripheral blood monocytes to differentiate into immunogenic dendritic cells in vitro. Gut Microbes 13, 1\u201320 (2021).","journal-title":"Gut Microbes"},{"key":"891_CR153","doi-asserted-by":"publisher","first-page":"886447","DOI":"10.3389\/fcimb.2022.886447","volume":"12","author":"CA Hobson","year":"2022","unstructured":"Hobson, C. A. et al. A Microbiota-Dependent Response to Anticancer Treatment in an In Vitro Human Microbiota Model: A Pilot Study With Hydroxycarbamide and Daunorubicin. Front. Cell Infect. Microbiol. 12, 886447 (2022).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"891_CR154","first-page":"199","volume":"22","author":"S Viaud","year":"2015","unstructured":"Viaud, S. et al. Gut microbiome anticancer immune Response.: really hot Sh.*t! Cell Death Differ. 22, 199\u2013214 (2015).","journal-title":"Gut microbiome anticancer immune Response.: really hot Sh.*t! Cell Death Differ."},{"key":"891_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01034-0","volume":"9","author":"D B\u00f6hm","year":"2025","unstructured":"B\u00f6hm, D. et al. The role of the gut microbiota in chemotherapy response, efficacy and toxicity: a systematic review. npj Precis. Oncol. 9, 265 (2025).","journal-title":"npj Precis. Oncol."},{"key":"891_CR156","doi-asserted-by":"publisher","unstructured":"Tang, Y., Li, Y., Chen, P., Zhong, S. & Yang, Y. Nucleic Acid Aptamer-Based Sensors for Bacteria Detection: A Review. Bio Essays 47, e202400111, https:\/\/doi.org\/10.1002\/bies.202400111 (2025).","DOI":"10.1002\/bies.202400111"},{"key":"891_CR157","doi-asserted-by":"publisher","first-page":"104767","DOI":"10.1016\/j.critrevonc.2025.104767","volume":"212","author":"D Wekking","year":"2025","unstructured":"Wekking, D. et al. The interplay between gut microbiota, antibiotics, and immune checkpoint inhibitors in patients with cancer: A narrative review with biological and clinical aspects. Crit. Rev. Oncol. Hematol. 212, 104767 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"891_CR158","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/s41591-021-01552-x","volume":"27","author":"C Mirzayi","year":"2021","unstructured":"Mirzayi, C. et al. Reporting guidelines for human microbiome research: the STORMS checklist. Nat. Med. 27, 1885\u20131892 (2021).","journal-title":"Nat. Med."},{"key":"891_CR159","doi-asserted-by":"publisher","first-page":"2495183","DOI":"10.1080\/19490976.2025.2495183","volume":"17","author":"Y Xu","year":"2025","unstructured":"Xu, Y., Gao, Z., Liu, J., Yang, Q. & Xu, S. Role of gut microbiome in suppression of cancers. Gut Microbes. 17, 2495183 (2025).","journal-title":"Gut Microbes."},{"key":"891_CR160","doi-asserted-by":"crossref","unstructured":"Sevcikova, A. et al., The impact of the microbiome on resistance to cancer treatment with chemotherapeutic agents and immunotherapy. Int. J. Mol. Sci. 23, 2022.","DOI":"10.3390\/ijms23010488"},{"key":"891_CR161","doi-asserted-by":"publisher","first-page":"1559521","DOI":"10.3389\/fmicb.2025.1559521","volume":"16","author":"A Safarchi","year":"2025","unstructured":"Safarchi, A. et al. Understanding dysbiosis and resilience in the human gut microbiome: biomarkers, interventions, and challenges. Front. Microbio. 16, 1559521 (2025).","journal-title":"Front. Microbio."},{"key":"891_CR162","doi-asserted-by":"publisher","first-page":"1507336","DOI":"10.3389\/fmicb.2025.1507336","volume":"16","author":"Y Huang","year":"2025","unstructured":"Huang, Y. et al. Role of gut microbiota in predicting chemotherapy-induced neutropenia duration in leukemia patients. Front. Microbiol. 16, 1507336 (2025).","journal-title":"Front. Microbiol."},{"key":"891_CR163","doi-asserted-by":"publisher","first-page":"106312","DOI":"10.1016\/j.compbiomed.2022.106312","volume":"151","author":"X Cheng","year":"2022","unstructured":"Cheng, X. et al. Fecal 16S rRNA sequencing and multi-compartment metabolomics revealed gut microbiota and metabolites interactions in APP\/PS1 mice. Comput. Biol. Med. 151, 106312 (2022).","journal-title":"Comput. Biol. Med."},{"key":"891_CR164","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/bib\/bbz155","volume":"22","author":"R Bharti","year":"2019","unstructured":"Bharti, R. & Grimm, D. G. Current challenges and best-practice protocols for microbiome analysis. Brief. Bioinforma. 22, 178\u2013193 (2019).","journal-title":"Brief. Bioinforma."},{"key":"891_CR165","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/19490976.2017.1286006","volume":"8","author":"MH Woodworth","year":"2017","unstructured":"Woodworth, M. H. et al. Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review. Gut Microbes. 8, 225\u2013237 (2017).","journal-title":"Gut Microbes"},{"key":"891_CR166","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"891_CR167","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"891_CR168","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.csbj.2022.12.053","volume":"21","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. MNNMDA: Predicting human microbe-disease association via a method to minimize matrix nuclear norm. Comput. Struct. Biotechnol. J. 21, 1414\u20131423 (2023).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"891_CR169","doi-asserted-by":"publisher","first-page":"127832","DOI":"10.1016\/j.micres.2024.127832","volume":"286","author":"N Tewari","year":"2024","unstructured":"Tewari, N. & Dey, P. Navigating commensal dysbiosis: Gastrointestinal host-pathogen interplay orchestrating opportunistic infections. Microbiol. Res. 286, 127832 (2024).","journal-title":"Microbiol. Res"},{"key":"891_CR170","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41577-023-00951-0","volume":"24","author":"SJ Blake","year":"2024","unstructured":"Blake, S. J. et al. Role of the microbiota in response to and recovery from cancer therapy. Nat. Rev. Immunol. 24, 308\u2013325 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"891_CR171","doi-asserted-by":"publisher","first-page":"e776","DOI":"10.1016\/S2352-3026(22)00223-X","volume":"9","author":"F Malard","year":"2022","unstructured":"Malard, F., Gaugler, B. & Mohty, M. Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice. Lancet Haematol. 9, e776\u2013e785 (2022).","journal-title":"Lancet Haematol."},{"key":"891_CR172","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1158\/1078-0432.CCR-23-2369","volume":"29","author":"A Rashidi","year":"2023","unstructured":"Rashidi, A. et al. Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial. Clin. Cancer Res. 29, 4920\u20134929 (2023).","journal-title":"Clin. Cancer Res."},{"key":"891_CR173","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s00203-023-03632-7","volume":"205","author":"M Summer","year":"2023","unstructured":"Summer, M. et al. Therapeutic and immunomodulatory role of probiotics in breast cancer: A mechanistic review. Arch. Microbiol. 205, 296 (2023).","journal-title":"Arch. Microbiol."},{"key":"891_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00869-5","volume":"20","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Regulatory role of short-chain fatty acids in inflammatory bowel disease. Cell Commun. Signal. 20, 64 (2022).","journal-title":"Cell Commun. Signal."},{"key":"891_CR175","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.aninu.2021.11.005","volume":"8","author":"M Akhtar","year":"2022","unstructured":"Akhtar, M. et al. Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation. Anim. Nutr. 8, 350\u2013360 (2022).","journal-title":"Anim. Nutr."},{"key":"891_CR176","doi-asserted-by":"publisher","first-page":"e068480","DOI":"10.1136\/bmjopen-2022-068480","volume":"13","author":"A Doug\u00e9","year":"2023","unstructured":"Doug\u00e9, A. et al. Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study). BMJ Open 13, e068480 (2023).","journal-title":"BMJ Open"},{"key":"891_CR177","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3389\/fimmu.2018.02195","volume":"9","author":"X Qi","year":"2018","unstructured":"Qi, X. et al. Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study. Front Immunol. 9, 2195 (2018).","journal-title":"Front Immunol."},{"key":"891_CR178","doi-asserted-by":"publisher","first-page":"e70501","DOI":"10.1002\/cam4.70501","volume":"14","author":"V Salvestrini","year":"2025","unstructured":"Salvestrini, V. et al. Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients. Cancer Med. 14, e70501 (2025).","journal-title":"Cancer Med."}],"container-title":["npj Biofilms and Microbiomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41522-025-00891-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41522-025-00891-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41522-025-00891-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:11:41Z","timestamp":1771434701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41522-025-00891-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":178,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1038\/s41522-025-00891-8","relation":{},"ISSN":["2055-5008"],"issn-type":[{"value":"2055-5008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}